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ΕΛΛΗΝΙΚΗ ΣΥΝΟΨΗ ΜΕΤΧΑΠΤΥΧΙΑΚΗΣ ΔΙΠΛΩΜΑΤΙΚΗΣ 
ΕΡΓΑΣΙΑΣ 
 
 
Τίτλος μελέτης  
Ο συνδυασμός Λεναλιδομίδης/Δεξαμεθαζόνης ,ως θεραπεία 
δεύτερης γραμμης σε Έλληνες και Κύπριους ασθενείς με 
ανθεκτικό/υποτροπιάζων πολλαπλό μυέλωμα.Μια 
πολυκεντρική,αναδρομική μελέτη παρατήρησης. 
 
Τύπος μελέτης και σχεδιασμός 
 
Πρόκειται για μια πολυκεντρική ,αναδρομική μελέτη παρατήρησης. 
Θα αναζητηθούν από τους ερευνητές ,τα ιατρικά αρχεία ασθενών 
με ανθεκτικό/υποτροπιάζων πολλαπλό μυέλωμα ,οι οποίοι λάβανε 
ως θεραπεία δεύτερης γραμμής ,τον συνδυασμό 
λεναλιδομίδης/δεξαμεθαζόνης . 
Κύριο καταληκτικό σημείο της μελέτης ,είναι η μέτρηση και η 
εκτίμηση της επιβίωσης χωρίς εξέλιξη της νόσου(PFS). 
Δευτερεύων καταληκτικό σημείο είναι η παρατήρηση και 
αξιολόγηση του χρόνου ,από την αρχή της θεραπείας δεύτερης 
γραμμής μέχρι την υποτροπή της νόσου ή τον θάνατο του 
ασθενούς από οποιοδήποτε αίτιο. 
Στη μελέτη αυτή θα συμπεριληφθούν το ελάχιστο 195 ασθενείς και 
θα παρατηρηθεί η PFS για 12 μήνες. 
Τα κέντρα που θα εντάξουν ασθενείς στη μελέτη θα είναι 15 
συνολικά σε Ελλάδα και Κύπρο. 
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1 LIST OF ABBREVIATIONS 
 
AE Adverse Event   
ASCT Autologous Stem Cell Transplantation  
ASH American Society of Hematology  
CI Confidence Interval   
CR Complete Response CRF Case Report Form   
CT Computed Tomography   
EBMT European Group for Blood and Marrow Transplantation  
ECOG Eastern Cooperative Oncology Group  
EFS Event-Free Survival   
FDA Food and Drug Administration  
FLC Free Light-Chain  
GPP Good Pharmacoepidemiology Practice 
HDT High-Dose Therapy  
IBMTR International Bone Marrow Transplant Registry   
ICF Informed Consent Form  
IGF-1 Insulin Growth Factor 1   
IL-6 Interleukin 6 
IRB Institutional Review Board  
ISS International Staging System  
MGUS Monoclonal gammopathy of undetermined significance 
MM  Multiple Myeloma  
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MR Minor Response   
MRI Magnetic Response Imaging  
NCCN National Comprehensive Cancer Network   
nCR Near Complete Response ORR Overall Response Rate  
OS Overall Survival  
PD Progressive Disease  
PFS Progression-Free Survival  
PR Partial Response  
REC Research ethics committee  
RRMM Relapsed or Refractory Multiple Myeloma 
SD Stable Disease  
TNF-α Tumor Necrosis Factor aplha 
TtNT   Time to Next Treatment  
TTP    Time to Progression  
VEGF Vascular Endothelial Growth Factor  
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2. PROTOCOL SYNOPSIS 
 
Study title 
 
“Second line therapy using Lenalidomide/Dexamethasone in 
Greek and Cypriot patients with Refractory/Relapsed Multiple 
Myeloma.An observational retrospective study.” 
 
 
Study type and design 
 
This observational ,retrospective study aims to evaluate disease 
progression and survival rates as well as to record treatment 
strategies used in common clinical practice with 
relapsed/refractory multiple myeloma patients after first relapse ,in 
Greece and Cyprus. 
 
Primary endpoint 
 
Evaluation of the 12 month progression-free survival rate in 
patients treated with Lenalidomide/Dexamethasone at 1st relapse. 
 
Secondary endpoint 
 
Time(months) from second line treatment initiation upon to disease 
progression or death from all causes,whatever comes first,in 
patients receiving therapy with Lenalidomide/Dexamethasone after 
first relapse. 
 
Time frame 
12 months 
Number of sites enrolling participants: 15 
Number of participants : 195 
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3. INTRODUCTION 
 
3.1 Background 
 
3.1.1 Epidemiology and pathogenesis of multiple myeloma 
 
Multiple myeloma is a hematologic disorder which is characterized 
by a proliferation of malignant, monoclonal plasma cells in the 
bone marrow (BM) and/or extramedullary sites, that appears in 
association with monoclonal protein in serum and/or urine, 
decreased normal immunoglobulin (Ig) levels, and lytic bone 
disease.[1] 
 
The American Cancer Society’s estimates for multiple myeloma in 
the United States for 2017, say that about 30,280 new cases will 
be diagnosed and about 12,590 deaths are expected to occur [2]. 
In Europe, 38.928 incidents of multiple myeloma and 24.283 
deaths were reported during 2012. In Greece, 567 new diagnoses 
and 380 deaths were recorded(2012). Multiple myeloma incidence 
and death rates are slightly higher for men compared to women 
[3,4]. Furthermore multiple myeloma is twice as common in black 
population compared to the white population.[5] 
 
Multiple myeloma evolves from a premalignant condition clinically 
recognized as Monoclonal gammopathy of undetermined 
significance .MGUS is present in 3% to 4% of the general 
population older than 50 years. Because MGUS is mostly 
asymptomatic and often detected as an incidental laboratory 
finding, only 10% of the patients with newly diagnosed multiple 
myeloma have a history of preexisting MGUS. However, studies 
have found that MGUS almost always precedes multiple myeloma 
and is associated with a risk for progression of approximately 1% 
per year. Smoldering multiple myeloma is an intermediate stage 
between MGUS and MM and is associated with a higher risk for 
progression of approximately 10% per year.[5] 
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Although there are treatment strategies available from early to 
relapsed multiple myeloma, it is thought to be an incurable disease 
due to the interactions between the  bone marrow and the multiple 
myeloma plasma cells. It has been found that the bone marrow 
environment strengthens multiple myelomas growth with secretion 
of cytokines, growth factors and anti-apoptosis factors like tumor 
necrosis factor alpha (TNF-a),interleukin 6 (IL-6),insulin-like growth 
factor 1 (IGF-1) and vascular endothelial growth factor (VEGF). As 
a result, factors that not only block the proliferation of the multiple 
myeloma cells but also affect the bone microenvironment, are 
definitely more beneficial in its treatment. 
 
 
3.1.2 Diagnosis and Staging 
 
Diagnosis of symptomatic multiple myeloma is based on the 
detection of a monoclonal paraprotein (M-protein) in the plasma 
with levels of 30 g/L and/or 10 % of clonal plasma cells of bone 
marrow and/or proven by biopsy plasmacytoma along with one (or 
more) of the CRAB symptoms. CRAB symptoms are 
hypercalcemia, renal problems, anemia and bone damage like 
thinning (osteoporosis) or lytic sessions [6]. 
 
Multiple myeloma staging is based on Durie-Salmon criteria 
developed in 1975, or on the recently developed International 
Staging for Multiple Myeloma criteria (ISS). ISS criteria are based 
on beta-2-microglobulin and albumin levels [7,8]. 
 
 
3.1.3 Treatment strategies 
 
Different therapeutic strategies exist, for patients dealing with 
multiple myeloma. Although there are clear guidelines for dealing 
with the disease when the first diagnosis occurs, there is not a 
generally accepted treatment strategy for patients dealing with 
relapsed and refractory multiple myeloma. [9,10] 
 
For patients with symptomatic multiple myeloma, who are eligible 
for transplantation, first line therapy strategy includes initial 
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induction with chemotherapy and later autologous stem cell 
transplantation followed (or not) by maintenance therapy. 
Maintenance therapy after ASCT aims in improving progression-
free survival (PFS) and overall survival(OS) [11,12]. 
 
For patients who are not eligible for transplantation, first line 
therapy includes chemotherapeutic factors use like melphalan with 
prednisolone. Furthermore, the addition of drugs like lenalidomide, 
thalidomide and bortezomib has shown great response and overall 
survival results [13,14,15] 
 
 
3.1.4 Refractory/Relapsed multiple myeloma definition and 
treatments 
 
Relapsed/refractory multiple myeloma (RRMM) is defined as a 
disease which becomes non-responsive or progressive on therapy 
or within 60 days from the last treatment in patients who had 
achieved a minimal response or better on previous therapy. 
 
Relapsed multiple myeloma is regarded as a recurrence of the 
disease after previous response, and has been defined based on 
objective laboratory and radiological criteria: ≥ 25 % increase of 
the serum or urine monoclonal protein (M-protein) or ≥ 25 % 
difference between involved and uninvolved serum free light 
chains from its nadir, respectively, or the development of new 
plasmacytomas or hyperkalaemia. In patients with non-secretory 
disease, relapse is defined as an increase of the bone marrow 
plasma cells. In general, an indication for relapse treatment has 
been defined as either the appearance or reappearance of one or 
more CRAB criteria or a rapid and consistent biochemical relapse.  
 
The relapse criteria have been developed by the European Bone 
and Marrow Transplantation team in association with the 
Autologous Blood and Marrow Transplant Registry team and the 
International Bone Marrow Transplant Registry team. These 
criteria are known as the “EBMT criteria” [28] 
 
Even though there are some therapeutic choices for multiple 
myeloma, it is an incurable disease with 1/3 of patients showing no 
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response to first line therapy and all of the patients relapsing some 
time after initial therapy [9,10]. 
 
Treatment choices for refractory/relapsed multiple myeloma are 
lenalidomide,thalidomide, bortezomib, alkylating agents, 
anthracyclines and corticosteroids as a monotherapy or different 
combinations [16,17,18] .Therapy must be individualized, taking 
upon consideration the first line treatment, the response to the first 
line treatment and the physical condition of the patient [19]. 
 
The combination of lenalidomide and dexamethasone has 
improved the outcome of patients with refractory/relapsed multiple 
myeloma. Randomized, phase III, clinical trials MM-009 and     
MM-010 that tested the Len/Dex combination in comparison with 
dexamethasone monotherapy revealed improved response and 
survival rates for RRMM patients. It has been proved that 
Lenalidomide/Dexamethasone combination has improved 
outcomes when administered after the  1st relapse. It is important 
to mention that patients receiving this combination after 1st relapse 
had better TTP,ORR and OS than those receiving the combination 
as a next line therapy (3rd or more). More specific TTP was 17,1 
months (after 1st line) against 10,6 months (later), ORR was 66,9% 
(after 1st line) against 56,8% (later) and OS was 42 months(after 
1st line) against 35,8 months (later) [22,31] 
 
Starting dose of lenalidomide should be monitored when in 
combination with dexamethasone in patients with RI or cytopenia. 
In addition, creatinine clearance and complete blood count (CBC) 
must be recorded before starting the 
Lenalidomide/Dexamethasone treatment. For patients with renal 
dysfunction starting dose must be reduced depending on the level 
of dysfunction [29] 
 
 
 
 
 
 
4 NECESSITY OF THE TRIAL 
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Lenalidomide and dexamethasone therapy has prolonged patients’ 
with refractory and relapsed multiple myeloma survival. Efficacy 
and safety of these drugs are sufficiently evidence based. 
Nevertheless, there is a lack of objective data regarding efficacy 
and the usage of this drug combination as second line therapy. 
As it is well known, the study population of a certain clinical trial 
must fulfill strict inclusion and exclusion criteria that may lead to a 
population, that is not necessarily representative of the patient 
population with refractory and relapsed multiple myeloma. 
Additionally, the outcomes of a certain clinical trial are observed 
under strictly controlled conditions that do not necessarily reflect 
the usual clinical practice. 
 
Due to the lack of knowledge regarding the patient outcomes in 
refractory and relapsed multiple myeloma receiving lenalidomide 
and dexamethasone combination treatment, this retrospective 
study aims to evaluate disease progression and survival rates as 
well as to record the treatment strategies used in common clinical 
practice with patients with RRMM after the first relapse in Greece 
and Cyprus. 
 
 
5 STUDY ENDPOINTS 
 
 
5.1 Primary endpoind 
 
Evaluation of 12 month progression free survival (PFS), of patients 
under Lenalidomide/Dexamethasone treatment after first relapse. 
 
 
 
5.2 Secondary endpoind(s) 
 
 Time (in months) from second line treatment initiation up to 
disease progression or death from all causes, whatever 
comes first, in patients receiving therapy with 
Lenalidomide/Dexamethasone after first relapse (clinical or 
laboratory). 
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 Time (in months) from second line treatment initiation up to 
disease progression or death from all causes, whatever 
comes first, in patients receiving therapy with 
Lenalidomide/Dexamethasone after symptomatic relapse 
(clinical). 
 Time (in months) from second line treatment initiation up to 
disease progression or death from all causes, whatever 
comes first in patients receiving therapy with 
Lenalidomide/Dexamethasone after asymptomatic relapse 
(laboratory).  
 Percentage of multiple myeloma patients achieving more or 
same partial response after second line treatment initiation 
(ORR rate).  
 Causes of choosing the Lenalidomide/Dexamethasone 
combination treatment including renal dysfunction, age, co-
morbidities and other factors. 
 
 
6 STUDY DESIGN 
 
6.1 Type of study 
 
It is a multicenter, two-countries, non-interventional, retrospective 
study of patients’ medical records with refractory/relapsed multiple 
myeloma, who fulfill the inclusion criteria. 
All the information needed for the purposes of this study, will be 
gathered in the electronic web-based Case Report Form (e- CRF). 
 
 
 
 
 
6.2 Clinical sites 
 
This clinical study will take place in 15 clinical sites around Greece 
and Cyprus, where clinical hematologists work. Doctors will be 
asked to retrieve the required information and fill the CRF. 
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6.3 Study population 
 
This study will include 195 patients with refractory/relapsed 
multiple myeloma that received  second line therapy with 
lenalidomide and dexamethasone combination between 1 January 
2012 until 31 December 2015 and fulfill all the study inclusion 
criteria depending on the investigators’ judgment. 
 
 
 
7 STUDY ENROLLMENT 
 
Patients with refractory/relapsed multiple myeloma (EBMT criteria), 
alive or not, who started second line therapy with 
lenalidomide/dexamethasone between 1 January 2012 to 31 
December 2015 will be detected through their medical history files. 
 
Patients will be included in the study consecutively, starting from 
the ones who received second line therapy with 
Lenalidomide/Dexamethasone closest to the endpoint date of 1 
January 2012. 
 
Inclusion of patients who have died is permitted only after 
REC/IRB’s approval that confirms that individual consent need not 
be obtained. In the case of not approving the exception of consent, 
patients who died will not be included in the study. 
 
 
 
 
7.1 Inclusion criteria 
 
Patients included in the study must fulfil ALL of the following 
criteria: 
 Male and female patients aged 18 or older. 
 Subjects must have a relapsed or refractory multiple 
myeloma diagnosis according to EBMT criteria. 
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 Subjects must have initiated second-line therapy with 
lenalidomide/dexamethasone between 1st January 2012 and 
31 December 2015. 
 Subjects must have available medical files/records and 
detailed historical data on their disease course and clinical 
management.  
 Provision of signed ICF for collecting and analyzing medical 
data pertinent to the objectives of this study. 
 
 
7.2 Exclusion criteria 
 
For the candidate subjects NONE of the following criteria should 
apply: 
 Prior malignancy (within the 3 years preceding initial 
diagnosis of multiple myeloma). 
 Subject participation in another interventional study. 
 Concurrent administration of anti-cancer regimens for 
malignancies other than multiple myeloma.  
 
 
 
8 STUDY PROCEDURE AND EVALUATIONS 
 
8.1 Study procedure 
 
Upon inclusion to the study the investigator must follow the 
procedures mentioned bellow: 
a) History file check and personal history in order to check 
compliance with the inclusion/exclusion criteria 
b) Explanation of the study goal to the patient. Let him take his 
time and read the informed consent. 
c) Retrieval of old data from the patient’s medical record and CRF 
completion. 
d) Provision of the completed CRF of every new patient to the 
clinical trial monitor and store a copy. 
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8.3 Study evaluations 
 
For the study purposes, the principal investigator (doctor) will 
collect and complete the CRF with the following patient 
information: 
 
 Signed informed consent 
 Patient eligibility for inclusion to the study 
(inclusion/exclusion criteria) 
 Demographics (age, gender, race) 
 Anthropometrics upon diagnosis and upon initiation of 
second line therapy  
 Medical history 
 Initial diagnosis information (including disease staging 
according to staging criteria of ISS) (prior to first relapse) 
 Laboratory findings (including blood screening with white 
blood cell type and blood smear testing, biochemical tests, 
including calcium and creatinine clearance, SPE, 
immunoprecipitation, urinary albumin and protein M, bone 
marrow biopsy and imaging studies). The information above 
will be collected from the medical records and will be at the 
closest timing since the initial diagnosis of the multiple 
myeloma, before initiation of second line therapy, at the first, 
documented response and upon relapse. 
 Information regarding first line therapy including starting 
date, the exact drugs used and the duration of treatment. 
 Data regarding the best response to the first line therapy 
 Data regarding diagnosis of refractory/relapsed multiple 
myeloma prior to the second line therapy.  
 Patient functional status prior to the second line therapy 
initiation. 
 Data of second line therapy (starting day, dose, date and 
cause for stopping or adjusting the dose). 
 Evaluation of disease progression during second line 
therapy. 
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9 STATISTICAL CONSIDERATIONS 
 
9.1 Sample size considerations 
 
The sample size is determined by the primary endpoint of the 
study, which is the percentage of the study population with 12 
months PFS (progression free survival). 
 
There is lack of published studies related to 12 month PFS. 
Because of that, we will use data from two clinical trials MM-009 
and MM-010, which claim that 14 month PFS of 
Lenalidomide/Dexamethazone as second line treatment 
approaches 50%. In order to estimate our sample size, we will use 
the 50% PFS for the 12 months. 
 
Therefore, supposing the PFS is 0,50 the number of patients is 
calculated: 
 
 
and s = (1-p) p 
 
 
 n is the number of patients  
 z=1,96 
 δ=0,07 is the precision and  
 p=0,05 is the given percentage 
 
Thus we may have sufficient precision if we use at least 195 
patients. 
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Given the above, the 95% confidence interval (CI) of the FPS 
percentage will be 43,0 - 57,0. 
 
Thus we may have sufficient precision if we use at least 195 
patients. 
 
{Sample size calculations were performed using SPSS 24 
software} 
 
 
9.2 Statistical methods and data analysis 
 
This study has a descriptive nature and it doesn’t aim in the 
confirmation or rejection of some hypothesis. Descriptive statistical 
analysis and epidemiological methods will be used for all the study 
data. 
Shapiro-Wilk control will be used to test the normality of the 
continuous variables distribution in order to determine the use of 
parametric or non-parametric methods for the data analysis. 
Continuous variables will be presented with the use of descriptive 
statistics (Mean, median, standard deviation) and categorical 
variables will be presented in frequency tables (N, %). 
 
Data related to study end-points (PFS, ORR, biochemical relapse, 
clinical relapse) will be calculated with their 95% confidence 
intervals. 
 
Logistic regression analysis will also be used to evaluate the effect 
of confounding factors in the percentage of Multiple Myeloma 
patients treated with Lenalidomide/Dexamethasone from the 1st 
relapse and didn’t have another relapse or did not die within 12 
months from the initiation of the second line treatment with 
Lenalidomide/Dexamethasone (PFS). 
 
In addition, Kaplan-Meier method will be used for secondary end-
points, having to do with evaluations of time-to-event and 
estimation of PFS and TtNT. Relevant diagrams will also be made. 
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Differences in PFS and TtNT between study groups of patients will 
be evaluated with Log-Rank testing. Furthermore, the effects of 
demographic, anthropometric and clinical characteristics in the 
PFS and TtNT will be evaluated by Cox regression analysis. 
 
Every statistical testing will have a 0,05 significance level. 
 
 
10 COLLECTION AND REPORT OF SAFETY DATA 
 
This is a non interventional, retrospective study and because of 
that there is no active collection and reporting of safety data. All 
the adverse events have been mentioned before and must have 
been noted by the doctors, according to pharmacovigilance 
requirements. However, if a serious adverse event is noted in the 
CRF, it will be asked from the investigators to report it in special 
adverse event report files so as to be processed. 
 
 
 
11 DATA HANDLING AND RECORD KEEPING 
 
 
11.1 Important documentation 
 
Before the initialization of the study the following files must be 
collected and archived: 
 Curriculum vitae of principal investigator and co-investigators 
(recent ones, signed and dated).  
 Dated and signed principal investigators agreement to the 
protocol. 
 Dated and signed principal investigators agreement to 
changes of the protocol (if needed). 
 Copy of approval correspondence from the responsible 
authorities in compliance with the local law for each of the 
clinical sites included in the study. 
 Investigators contract.  
 Financial contracts. 
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11.2 Important files and storage 
 
 The investigator should maintain complete and accurate trial 
documents in a safe place (fire and water protected). 
 Special attention should be paid to updated documents. 
 Attention should be paid to any e-records that must be used 
within an adequate document management system that is 
validated and the access protected by password and specific 
identification. Adding or changing e-data must be controlled 
by an audit trail. Maintain a security system that prevents 
unauthorized access to the data 
 The investigator should take measures to prevent accidental 
or premature destruction of these documents. 
 
 
11.3 Case report forms 
 
Because electronic CRF will be used, attention should be paid to 
any e-records that must be used within an adequate document 
management system that is validated and the access protected by 
password and specific identification. 
Adding or changing e-data must be controlled by an audit trail. 
Maintain a security system that prevents unauthorized access to 
the data 
 
 
 
11.4 Protocol deviation 
 
Protocol deviations/changes are permitted only with written 
agreement from the sponsor and documented approval from the 
REC. 
 
11.5 Premature discontinuation of the trial 
 
11.5.1 Investigator termination 
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If the investigator decides to terminate or suspend a trial, the 
sponsor and the REC should both be informed promptly and given 
a written explanation for termination.  
 
11.5.2 Sponsor termination 
 
If the sponsor decides to terminate or suspend a trial the 
investigator should inform the institution and provide the REC with 
a written explanation.  
 
11.5.3 REC termination 
 
If the REC terminates or suspends a trial, the investigator should 
inform the institution, the health authorities where applicable and 
the sponsor, and provide the latter with a written explanation. 
 
 
12 ETHICAL ISSUES 
 
12.1 Ethical standard 
 
This trial was designed and will be conducted in accordance to the 
Helsinki Declaration(lastly published on Oct 2008),to the guidelines 
of good pharmacoepidemiology practice and to the local 
regulations. 
 
 
12.2 Institutional review board 
 
The protocol, informed consent forms, recruitment materials and 
all participant materials will be submitted to the local IRB for review 
and approval. 
Approval of both the protocol and the consent form must be 
obtained before any participant is enrolled. 
 
12.3 Consent procedures and documentation 
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Informed consent is a process that is initiated prior to the 
individual’s agreeing to participate in the study and continues 
throughout the individual’s study participation. Extensive 
discussion of risks and possible benefits of participation will be 
provided to the participants and their families. The investigator will 
explain the research study to the participant and answer any 
questions that may arise. 
The participants may withdraw consent at any time throughout the 
course of trial. A copy of the informed consent document will be 
given to the participants for their records. The rights and welfare of 
the participants will be protected by emphasizing to them that the 
quality of their medical care will not be adversely affected if they 
decline to participate in this study. 
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